Market Outlook

The heart failure drugs market, valued at USD 7.84 billion in 2025, is projected to reach USD 9.19 billion in 2026 and USD 12.31 billion by 2035 (this represents the opportunity only for those drugs that are primarily indicated for heart failure).

Global Heart Failure Drugs Market Growth 2025 to 2035

See What’s in the Full Report – Request Your Complimentary Insights!

Market Report: Key Takeaways

Market Size & Trends

In terms of type of heart failure, chronic heart failure holds the highest share (above 95%) of the current market.
With respect to type of therapy, monotherapies dominate the complete current market.
Based on type of molecule, small molecules capture the largest share (above 95%) of the current market; this trend is unlikely to change in the future.
Amongst the routes of administration, oral route captures the most (above 95%) of the current market.
In terms of geographical regions, North America currently holds the highest market share (above 40%).

Key Market Statistics

Market Size in 2026: $ 9.19 Billion
Estimated Market Size in 2035: $ 12.31 Billion
North America: Largest market in 2026
Asia-Pacific: Fastest growing region

Market Introduction

Heart failure is a chronic condition in which the heart is unable to pump sufficient blood into different organs. Further, in order to mitigate the growing incidence, pharmaceutical companies have developed heart failure drugs that can target wide range of conditions, such as managing fluid build-up, improving cardiac contractility, controlling blood pressure and addressing the root causes of heart failure. According to the Heart Failure Society of America, nearly 6.7 million Americans above the age of 20 are currently living with heart failure condition, which is estimated to reach 10.3 million by 2040.

To date, several heart failure drugs have been developed by the pharmaceutical companies to treat patients with heart failure conditions. Some examples of the heart failure drug class that are approved by the FDA are angiotensin-converting enzyme (ACE) inhibitors, diuretics, angiotensin receptor blockers (ARBs), aldosterone antagonists, and beta-blockers. Over time, extensive research and clinical advancements have enabled experts to incorporate newer heart failure drugs as well as congenital heart defect devices as transformative approaches in heart failure management. These modern therapies, including ARNI (angiotensin receptor-neprilysin inhibitors), SGLT2 inhibitors, and mineralocorticoid receptor antagonists offer a more comprehensive mechanism of action that targets multiple pathways involved in cardiac remodeling, fluid retention, and neurohormonal activation.

The market for heart failure therapeutics is expanding steadily and remains dynamic, with numerous pharmaceutical companies investing heavily in research and development. These investments build upon scientific progress in novel drug mechanisms, combination strategies, and innovative delivery approaches. With continuous innovation in this field, experts anticipate that the adoption of advanced heart failure drugs will rise significantly, which will drive robust market growth in the coming years.

Market Segmentation

Based on our market research, we have segmented the Heart Failure Drugs Market into type of heart failure, type of therapy, type of molecule, route of administration, geographical regions.

By Type of Heart Failure

Chronic Heart Failure
Others

By Type of Therapy

Monotherapies
Combination Therapies

By Type of Molecule

Small Molecules
Biologics

By Route of Administration

Oral
Intramyocardial
Subcutaneous
Intravenous
Intracoronary

By Geographical Regions

North America
- US
- Canada
Europe
- Germany
- France
- UK
- Italy
- Spain
Asia-Pacific
- China
- Japan
- India
- South Korea
Rest of the World

Your Business is Unique – Why Shouldn’t Your Report Be?

Heart Failure Drugs Market Key Insights

What are the Key Drivers for Heart Failure Drugs Market Growth?

Innovations in Novel Drug Class: SGLT2 inhibitors and ARNIs are novel drug classes backed by strong clinical data, demonstrating a notable decrease in patient mortality rates. Further, SGLT2 inhibitors can reduce heart failure hospitalization risk. Notably, the combination of both SGLT2 inhibitors and ARNIs demonstrates significant effectiveness in the treatment of heart failure.
Growing Geriatric Population and Rising Prevalence of Heart Failure: Heart failure primarily affects older adults. Factors, such as hypertension, obesity, coronary artery disease, and diabetes commonly cause or worsen the condition. The prevalence of heart failure increases significantly with age and often exceeds 10% in individuals over 70 due to the accumulation of multiple risk factors.

What are the Main Challenges in Market Growth?

High Failure Rates in Drug Development: Heart failure drug development faces significant hurdles and low success rates due to factors like insufficient clinical efficacy, poor drug specificity, and uncontrolled toxicity. Moreover, approval rates for new molecular entities (NMEs) for cardiovascular treatments have hit historic lows, driving up heart failure drug development costs.
Limited Research Funding: The high cost of developing heart failure drugs stems from substantial investments in clinical trials, stringent regulatory requirements, and enrollment challenges. The limited funding from governments and private sectors often hinders the completion of research projects, posing significant obstacles for stakeholders in this domain.

Recent Developments in Heart Failure Drugs Market

In April 2026, the U.S. Food and Drug Administration approved the first generics of FARXIGA® (dapagliflozin) tablets. This SGLT2 inhibitor is indicated for use in adults with type 2 diabetes mellitus, and to reduce the risk of hospitalization for heart failure.
In January 2026, Viatris announced the launch of Inpefa® (sotagliflozin), SGLT1/2 an inhibitor for the treatment of heart failure, in the United Arab Emirates (UAE).
In September 2025, Bayer announced new data from the pivotal Phase III FINEARTS-HF trial for KERENDIA® (finerenone) at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025, held in Minneapolis, Minnesota.

Industry Experts on Heart Failure Drugs Market Trends

The market for heart failure has a transformative future and is likely to remain progressive in the coming years.

Christoph Koenen (Head of Clinical Development and Operations, Bayer Pharmaceuticals) stated,

“I believe the burden that heart failure places are immense, not only on the individual patient, but also on healthcare professionals and the healthcare system as a whole. Heart failure remains the leading cause of hospitalization among elderly patients worldwide. With an estimated 64 million people affected globally, this enormous patient population translates into a correspondingly heavy strain on healthcare resources. The overall expenditure on heart failure treatment is extraordinarily high, with the majority of these costs stemming from hospital stays. This reality underscores the critical importance of clinical studies aimed at reducing hospitalization, improving patient outcomes, and ultimately alleviating the pressure on healthcare systems worldwide.”

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following third-party discussions:

Professor of Medical Cardiology, Very Large Organization, United Kingdom, Europe
Professor and Head of Advanced Heart Failure Wing, Very Large Organization, United States, North America
Clinical Associate Professor and Director of Clinical Research, Large Organization, United States, North America
Doctor of Medicine, Very Large Organization, United States, North America
Professor, Very Large Organization, United States, North America
Professor of Medicine and Heart Failure Specialist (Former Chair of Division for Circulatory Failure), Very Large Organization, United States, North America
Senior Consultant Cardiologist, Large Organization, India, Asia
Chair of DIGIT-HF trial, Very Large Organization, Germany, Europe
Cardiologist and Clinical Researcher, Very Large Organization, United States, North America

Pay Only for What You Need – The Best Way to Optimize

Which Type of Heart Failure Accounts for the Largest Share in the Heart Failure Drugs Market?

In 2026, the chronic heart failure segment is projected to hold the highest market share (above 95%). This is primarily because of its high prevalence, long-term management requirements, and sustained demand for ongoing pharmacological therapies. Moreover, this segment is likely to grow at a decent CAGR during the forecast period. It is worth highlighting that Empagliflozin / Jardiance, a heart failure monotherapy drug, first approved in 2021, generated sales worth USD 4.4 billion in 2025.

Regional Analysis: Which Regions are Showing the Fastest Growth in Heart Failure Domain?

North America: Dominating the Market by Securing Highest Share

According to our projections, North America is likely to capture the majority (more than 40%) of the heart failure drugs market share in 2026. Further, we anticipate that Asia-Pacific would grow at a relatively faster pace till 2035. Within the heart failure drugs market, the US has emerged as a hub for heart failure drug developers, supported by its innovation-friendly regulatory policies and a highly skilled workforce. This regional concentration facilitates efficient scaling of heart failure drugs, from early-stage development to commercial supply.

UAE Heart Failure Treatment Drugs Market

It is worth highlighting that the Emirates Drug Establishment has issued a new decision to reduce the retail prices of 168 pharmaceutical products across the UAE, covering a wide range of chronic and critical illnesses. The decision includes reductions in the cost of advanced therapies prescribed for patients with chronic heart muscle failure.

Which Type of Molecule Will Dominate the Heart Failure Drugs Market?

In 2026, the small molecule segment is likely to dominate the overall market share (more than 95%). This dominance stems from established efficacy of small molecules as oral therapies, like beta-blockers, ACE inhibitors, ARBs, and SGLT2 inhibitors, which form the standard of care for HFrEF and HFpEF due to proven mortality benefits in trials like DAPA-HF and EMPEROR-Reduced.
The biologics segment is likely to grow at a higher CAGR (52.0%) during the forecast period. This growth is driven by biologics enabling personalized therapies addressing genetic and inflammatory drivers of heart failure progression, capturing premium pricing and niche markets unmet by generic small molecules.

Global Heart Failure Drugs Market Size by Type of Molecule, 2035

Which Route of Administration Accounts for the Largest Share in the Heart Failure Drugs Market?

According to the heart failure drugs market forecast, the oral route of administration currently accounts for more than 95% of the overall market revenue. This can be attributed to its convenience, high patient adherence for long-term chronic management, and ease of self-administration at home.
Till 2035, the market for drugs that can be administered by intramyocardial route is likely to grow at a faster pace (34.9%). This can be attributed to its ability to deliver therapeutics directly into the myocardium, and improved cardiac function in advanced heart failure patients.

Global Heart Failure Drugs Market Size by Route of Administration, 2035

Amongst Monotherapies and Combination Therapies, Which Segment Holds the Highest Share in the Heart Failure Drugs Market?

According to the heart failure drugs market forecast, currently the monotherapies segment accounts for the entire market revenue. This is due to their established clinical guidelines as first-line treatment, better patient adherence, and cost-effectiveness compared to combination regimens in the initial management of heart failure.
The combination therapies segment is likely to grow at a higher CAGR (34.4%) during the forecast period. This is due to the rising adoption of multi-drug regimens, such as quadruple therapy (ARNI, beta-blockers, MRA, and SGLT2i), which deliver synergistic effects, superior clinical outcomes like reduced mortality and hospitalization, and improved patient compliance compared to monotherapies.

Get an Instant Quote in 10 Minutes. Lowest Price Guaranteed

Scope of Heart Failure Drugs Market Report

Key Report Attribute	Details
Historical Trend	Since 2021
Forecast Period	Till 2035
Market Size 2026	$ 9.19 Billion
Market Size 2035	$ 12.31 Billion
Segments Covered	Type of Heart Failure Type of Therapy Type of Molecule Route of Administration Geographical Regions
Key Players Profiled	AstraZeneca Boehringer Ingelheim Bristol Myers Squibb Corteria Pharmaceuticals Cytokinetics Eli Lilly Hyloris Pharmaceuticals Jiangsu Hengrui Pharmaceuticals Novo Nordisk Sardocor StemCardia Tasly Pharmaceuticals Tenaya Therapeutics (A complete list of companies captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization
Excel Data Packs (Complimentary)	Available

+ 1. BACKGROUND

1.1. Context

1.2. Project Objectives

+ 2. RESEARCH METHODOLOGY

2.1. Chapter Overview

2.2. Research Assumptions

2.2.1. Market Landscape and Market Trends

2.2.2. Market Forecast and Opportunity Analysis

2.2.3. Comparative Analysis

2.3. Database Building

2.3.1. Data Collection

2.3.2. Data Validation

2.3.3. Data Analysis

2.4. Project Methodology

2.4.1. Secondary Research

2.4.1.1. Annual Reports

2.4.1.2. Academic Research Papers

2.4.1.3. Company Websites

2.4.1.4. Investor Presentations

2.4.1.5. Regulatory Filings

2.4.1.6. White Papers

2.4.1.7. Industry Publications

2.4.1.8. Conferences and Seminars

2.4.1.9. Government Portals

2.4.1.10. Media and Press Releases

2.4.1.11. Newsletters

2.4.1.12. Industry Databases

2.4.1.13. Roots Proprietary Databases

2.4.1.14. Paid Databases and Sources

2.4.1.15. Social Media Portals

2.4.1.16. Other Secondary Sources

2.4.2. Primary Research

2.4.2.1. Types of Primary Research

2.4.2.1.1. Qualitative Research

2.4.2.1.2. Quantitative Research

2.4.2.1.3. Hybrid Approach

2.4.2.2. Advantages of Primary Research

2.4.2.3. Techniques for Primary Research

2.4.2.3.1. Interviews

2.4.2.3.2. Surveys

2.4.2.3.3. Focus Groups

2.4.2.3.4. Observational Research

2.4.2.3.5. Social Media Interactions

2.4.2.4. Key Opinion Leaders Considered in Primary Research

2.4.2.4.1. Company Executives (CXOs)

2.4.2.4.2. Board of Directors

2.4.2.4.3. Company Presidents and Vice Presidents

2.4.2.4.4. Research and Development Heads

2.4.2.4.5. Technical Experts

2.4.2.4.6. Subject Matter Experts

2.4.2.4.7. Scientists

2.4.2.4.8. Doctors and Other Healthcare Providers

2.4.2.5. Ethics and Integrity

2.4.2.5.1. Research Ethics

2.4.2.5.2. Data Integrity

2.4.3. Analytical Tools and Databases

2.5. Robust Quality Control

+ 3. MARKET DYNAMICS

3.1. Chapter Overview

3.2. Forecast Methodology

3.2.1. Top-down Approach

3.2.2. Bottom-up Approach

3.2.3. Hybrid Approach

3.3. Market Assessment Framework

3.3.1. Total Addressable Market (TAM)

3.3.2. Serviceable Addressable Market (SAM)

3.3.3. Serviceable Obtainable Market (SOM)

3.3.4. Currently Acquired Market (CAM)

3.4. Forecasting Tools and Techniques

3.4.1. Qualitative Forecasting

3.4.2. Correlation

3.4.3. Regression

3.4.4. Extrapolation

3.4.5. Convergence

3.4.6. Sensitivity Analysis

3.4.7. Scenario Planning

3.4.8. Data Visualization

3.4.9. Time Series Analysis

3.4.10. Forecast Error Analysis

3.5. Key Considerations

3.5.1. Demographics

3.5.2. Government Regulations

3.5.3. Reimbursement Scenarios

3.5.4. Market Access

3.5.5. Supply Chain

3.5.6. Industry Consolidation

3.5.7. Pandemic / Unforeseen Disruptions Impact

3.6. Limitations

+ 4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview

4.2. Market Dynamics

4.2.1. Time Period

4.2.1.1. Historical Trends

4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage

4.2.2.1. Major Currencies Affecting the Market

4.2.2.2. Factors Affecting Currency Fluctuations on the Industry

4.2.2.3. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Currency Exchange Rate

4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market

4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession

4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market

4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt

4.2.5. Inflation

4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy

4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates

4.2.6.1. Interest Rates and Their Impact on the Market

4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis

4.2.7.1. Type of Commodity

4.2.7.2. Origins and Destinations

4.2.7.3. Values and Weights

4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics

4.2.8.1. Import Scenario

4.2.8.2. Export Scenario

4.2.8.3. Trade Policies

4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers

4.2.8.5. Impact of Trade Barriers on the Market

4.2.9. War Impact Analysis

4.2.9.1. Russian-Ukraine War

4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors

4.2.10.1. Global Economic Impact

4.2.10.2. Industry-specific Impact

4.2.10.3. Government Response and Stimulus Measures

4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators

4.2.11.1. Fiscal Policy

4.2.11.2. Consumer Spending

4.2.11.3. Gross Domestic Product

4.2.11.4. Employment

4.2.11.5. Taxes

4.2.11.6. Stock Market Performance

4.2.11.7. Cross Border Dynamics

4.3. Conclusion

+ 5. EXECUTIVE SUMMARY

5.1. Executive Summary: Market Landscape

5.2. Executive Summary: Market Trends

5.3. Executive Summary: Market Forecast and Opportunity Analysis

+ 6. INTRODUCTION

6.1. Overview of Heart Failure

6.2. Stages of Heart Failure

6.3. Factors Contributing to Heart Failure

6.4. Heart Failure Treatment and Management

6.5. Future Perspectives

+ 7. MARKET LANDSCAPE

7.1. Methodology and Key Parameters

7.2. Heart Failure Drugs: Overall Market Landscape

7.2.1. Analysis by Stage of Development

7.2.2. Analysis by Type of Molecule

7.2.3. Analysis by Type of Biologic

7.2.4. Analysis by Type of Therapy

7.2.5. Analysis by Mechanism of Action

7.2.6. Analysis by Route of Administration

7.2.7. Analysis by Target Patient Population

7.2.8. Analysis by Type of Heart Failure

7.3. Heart Failure Drug Developers: Market Landscape

7.3.1. Analysis by Year of Establishment

7.3.2. Analysis by Company Size

7.3.3. Analysis by Location of Headquarters

7.3.4. Most Active Players: Analysis by Number of Drugs Developed

+ 8. COMPANY PROFILES

8.1. Chapter Overview

8.2. AstraZeneca

8.2.1. Company Overview

8.2.2. Heart Failure Drugs Portfolio

8.2.3. Key Initiatives

8.3. Boehringer Ingelheim

8.4. Bristol Myers Squibb

8.5. Corteria Pharmaceuticals

8.6. Cytokinetics

8.7. Eli Lilly

8.8. Hyloris Pharmaceuticals

8.9. Suncadia Pharmaceuticals

8.10. Novo Nordisk

8.11. Sardocor

8.12. StemCardia

8.13. Tasly Pharmaceuticals

8.14. Tenaya Therapeutics

+ 9. CLINICAL TRIAL ANALYSIS

9.1. Methodology and Key Parameters

9.2. Heart Failure Drugs: Clinical Trial Analysis

9.2.1. Analysis by Trial Registration Year

9.2.2. Analysis by Trial Status

9.2.3. Analysis by Trial Registration Year and Trial Status

9.2.4. Analysis by Patients Enrolled by Trial Phase

9.2.5. Analysis by Patients Enrolled by Trial Registration Year

9.2.6. Analysis by Trial Phase

9.2.7. Analysis by Type of Sponsor / Collaborator

9.2.8. Analysis by Patient Gender

9.2.9. Analysis by Study Design

9.2.10. Analysis by Target Patient Population

9.2.11. Most Active Industry Players: Analysis by Number of Clinical Trials

9.2.12. Most Active Non-Industry Players: Analysis by Number of Clinical Trials

9.2.13. Geographical Distribution of Trials and Number of Patients Enrolled

9.2.14. Analysis of Clinical Trials by Trial Status and Geography

9.2.15. Analysis of Patients Enrolled by Trial Status and Geography

+ 10. DRUG FAILURE ANALYSIS

10.1. Methodology and Key Parameters

10.2. Heart Failure Drugs: Drug Failure Analysis

10.2.1. Analysis by Trial Phase

10.2.2. Analysis by Trial Status

10.2.3. Analysis by Reason of Drug Discontinuation

10.2.4. Analysis by Study Start Year and Year of Discontinuation

10.2.5. Analysis by Type of Heart Failure

10.2.6. Analysis by Type of Sponsor

10.2.7. Analysis by Geographical Region

+ 11. MARKET IMPACT ANALYSIS

11.1. Market Drivers

11.2. Market Restraints

11.3. Market Opportunities

11.4. Market Challenges

+ 12. GLOBAL HEART FAILURE MARKET

12.1. Key Assumptions and Methodology

12.2. Global Heart Failure Drugs Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

12.3. Multivariate Scenario Analysis

12.3.1. Global Heart Failure Drugs Market, Forecasted Estimates (Till 2035), Conservative Scenario

12.3.2. Global Heart Failure Drugs Market, Forecasted Estimates (Till 2035), Optimistic Scenario

12.4. Key Market Segments

+ 13. HEART FAILURE MARKET, BY TYPE OF HEART FAILURE

13.1. Key Assumptions and Methodology

13.2. Heart Failure Drugs Market: Distribution by Type of Heart Failure

13.2.1. Heart Failure Drugs Market for Chronic Heart Failure: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

13.2.2. Heart Failure Drugs Market for Others: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

13.3. Data Triangulation and Validation

+ 14. HEART FAILURE MARKET, BY TYPE OF THERAPY

14.1. Key Assumptions and Methodology

14.2. Heart Failure Drugs Market: Distribution by Type of Therapy

14.2.1. Heart Failure Drugs Market for Monotherapies: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

14.2.2. Heart Failure Drugs Market for Combination Therapies: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

14.3. Data Triangulation and Validation

+ 15. HEART FAILURE MARKET, BY TYPE OF MOLECULE

15.1. Key Assumptions and Methodology

15.2. Heart Failure Drugs Market: Distribution by Type of Molecule

15.2.1. Heart Failure Drugs Market for Small Molecules: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

15.2.2. Heart Failure Drugs Market for Biologics: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

15.3. Data Triangulation and Validation

+ 16. HEART FAILURE MARKET, BY ROUTE OF ADMINISTRATION

16.1. Key Assumptions and Methodology

16.2. Heart Failure Drugs Market: Distribution by Route of Administration

16.2.1. Heart Failure Drugs Market for Oral Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

16.2.2. Heart Failure Drugs Market for Subcutaneous Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

16.2.3. Heart Failure Drugs Market for Intramyocardial Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

16.2.4. Heart Failure Drugs Market for Intravenous Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

16.2.5. Heart Failure Drugs Market for Intracoronary Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

16.3. Data Triangulation and Validation

+ 17. HEART FAILURE MARKET, BY GEOGRAPHICAL REGIONS

17.1. Heart Failure Drugs Market: Distribution by Geographical Regions

17.1.1. Heart Failure Drugs Market in North America: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

17.1.1.1. Heart Failure Drugs Market in the US: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

17.1.1.2. Heart Failure Drugs Market in Canada: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

17.1.2. Heart Failure Drugs Market in Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

17.1.2.1. Heart Failure Drugs Market in Germany: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

17.1.2.2. Heart Failure Drugs Market in France: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

17.1.2.3. Heart Failure Drugs Market in UK: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

17.1.2.4. Heart Failure Drugs Market in Italy: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

17.1.2.5. Heart Failure Drugs Market in Spain: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

17.1.2.6. Heart Failure Drugs Market in Rest of Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

17.1.3. Heart Failure Drugs Market in Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

17.1.3.1. Heart Failure Drugs Market in China: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

17.1.3.2. Heart Failure Drugs Market in Japan: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

17.1.3.3. Heart Failure Drugs Market in India: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

17.1.3.4. Heart Failure Drugs Market in South Korea: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

17.1.3.5. Heart Failure Drugs Market in Rest of Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

17.1.4. Heart Failure Drugs Market in Rest of the World: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

17.2. Data Triangulation and Validation

+ 18. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

18.1. Heart Failure Drugs Market in North America: Distribution by Type of Heart Failure

18.1.1. Heart Failure Drugs Market in North America for Chronic Heart Failure, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

18.1.2. Heart Failure Drugs Market in North America for Others, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

18.2. Heart Failure Drugs Market in North America: Distribution by Type of Therapy

18.2.1. Heart Failure Drugs Market in North America for Monotherapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

18.2.2. Heart Failure Drugs Market in North America for Combination Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

18.3. Heart Failure Drugs Market in North America: Distribution by Type of Molecule

18.3.1. Heart Failure Drugs Market in North America for Small Molecules, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

18.3.2. Heart Failure Drugs Market in North America for Biologics, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

18.4. Heart Failure Drugs Market in North America: Distribution by Route of Administration

18.4.1. Heart Failure Drugs Market in North America for Oral Route, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

18.4.2. Heart Failure Drugs Market in North America for Subcutaneous Route, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

18.4.3. Heart Failure Drugs Market in North America for Intramyocardial Route, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

18.4.4. Heart Failure Drugs Market in North America for Intravenous Route, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

18.4.5. Heart Failure Drugs Market in North America for Intracoronary Route, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

+ 19. MARKET OPPORTUNITY ANALYSIS: EUROPE

19.1. Heart Failure Drugs Market in Europe: Distribution by Type of Heart Failure

19.1.1. Heart Failure Drugs Market in Europe for Chronic Heart Failure, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

19.1.2. Heart Failure Drugs Market in Europe for Others, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

19.2. Heart Failure Drugs Market in Europe: Distribution by Type of Therapy

19.2.1. Heart Failure Drugs Market in Europe for Monotherapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

19.2.2. Heart Failure Drugs Market in Europe for Combination Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

19.3. Heart Failure Drugs Market in Europe: Distribution by Type of Molecule

19.3.1. Heart Failure Drugs Market in Europe for Small Molecules, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

19.3.2. Heart Failure Drugs Market in Europe for Biologics, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

19.4. Heart Failure Drugs Market in Europe: Distribution by Route of Administration

19.4.1. Heart Failure Drugs Market in Europe for Oral Route, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

19.4.2. Heart Failure Drugs Market in Europe for Subcutaneous Route, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

19.4.3. Heart Failure Drugs Market in Europe for Intramyocardial Route, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

19.4.4. Heart Failure Drugs Market in Europe for Intravenous Route, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

19.4.5. Heart Failure Drugs Market in Europe for Intracoronary Route, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

+ 20. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

20.1. Heart Failure Drugs Market in Asia-Pacific: Distribution by Type of Heart Failure

20.1.1. Heart Failure Drugs Market in Asia-Pacific for Chronic Heart Failure, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.1.2. Heart Failure Drugs Market in Asia-Pacific for Others, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.2. Heart Failure Drugs Market in Asia-Pacific: Distribution by Type of Therapy

20.2.1. Heart Failure Drugs Market in Asia-Pacific for Monotherapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.2.2. Heart Failure Drugs Market in Asia-Pacific for Combination Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.3. Heart Failure Drugs Market in Asia-Pacific: Distribution by Type of Molecule

20.3.1. Heart Failure Drugs Market in Asia-Pacific for Small Molecules, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.3.2. Heart Failure Drugs Market in Asia-Pacific for Biologics, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.4. Heart Failure Drugs Market in Asia-Pacific: Distribution by Route of Administration

20.4.1. Heart Failure Drugs Market in Asia-Pacific for Oral Route, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.4.2. Heart Failure Drugs Market in Asia-Pacific for Subcutaneous Route, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.4.3. Heart Failure Drugs Market in Asia-Pacific for Intramyocardial Route, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.4.4. Heart Failure Drugs Market in Asia-Pacific for Intravenous Route, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.4.5. Heart Failure Drugs Market in Asia-Pacific for Intracoronary Route, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

+ 21. MARKET OPPORTUNITY ANALYSIS: REST OF THE WORLD

21.1. Heart Failure Drugs Market in Rest of the World: Distribution by Type of Heart Failure

21.1.1. Heart Failure Drugs Market in Rest of the World for Chronic Heart Failure, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.1.2. Heart Failure Drugs Market in Rest of the World for Others, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.2. Heart Failure Drugs Market in Rest of the World: Distribution by Type of Therapy

21.2.1. Heart Failure Drugs Market in Rest of the World for Monotherapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.2.2. Heart Failure Drugs Market in Rest of the World for Combination Therapies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.3. Heart Failure Drugs Market in Rest of the World: Distribution by Type of Molecule

21.3.1. Heart Failure Drugs Market in Rest of the World for Small Molecules, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.3.2. Heart Failure Drugs Market in Rest of the World for Biologics, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.4. Heart Failure Drugs Market in Rest of the World: Distribution by Route of Administration

21.4.1. Heart Failure Drugs Market in Rest of the World for Oral Route, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.4.2. Heart Failure Drugs Market in Rest of the World for Subcutaneous Route, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.4.3. Heart Failure Drugs Market in Rest of the World for Intramyocardial Route, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.4.4. Heart Failure Drugs Market in Rest of the World for Intravenous Route, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.4.5. Heart Failure Drugs Market in Rest of the World for Intracoronary Route, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

+ 22. HEART FAILURE MARKET, SALES FORECAST OF DRUGS

22.1. Approved and Phase III Heart Failure Drugs: Sales Forecast

22.1.1. Empagliflozin / Jardiance: Sales Forecast

22.1.2. Farxiga / Dapagliflozin: Sales Forecast

22.1.3. Kerendia / Finerenone: Sales Forecast

22.1.4. Furoscix / Furosemide: Sales Forecast

22.1.5. Injectafer / Ferinject: Sales Forecast

22.1.6. Verquvo / Vericiguat: Sales Forecast

22.1.7. Sotagliflozin / Inpefa: Sales Forecast

22.1.8. Baxdrostat: Sales Forecast

22.1.9. Balcinrenone / Dapagliflozin: Sales Forecast

22.1.10. Vicadrostat / BI 690517: Sales Forecast

22.1.11. Ziltivekimab: Sales Forecast

22.1.12. Revascor / Rexlemestrocel L: Sales Forecast

22.1.13. Maridebart cafraglutid: Sales Forecast

22.1.14. Omecamtiv Mecarbil: Sales Forecast

22.1.15. Ferric Derisomaltose: Sales Forecast

22.1.16. JRM-001: Sales Forecast

22.1.17. Enavogliflozin / Envlo: Sales Forecast

+ 23. CONCLUDING REMARKS

+ 24. EXECUTIVE INSIGHTS

24.1. Chapter Overview

24.2. Company A

24.2.1. Company Snapshot

24.2.2. Interview Transcript: Professor of Medical Cardiology

24.3. Company B

24.3.1. Company Snapshot

24.3.2. Interview Transcript: Professor and Head of Advanced Heart Failure Wing

24.4. Company C

24.4.1. Company Snapshot

24.4.2. Interview Transcript: Clinical Associate Professor & Director of Clinical Research

24.5. Company D

24.5.1. Company Snapshot

24.5.2. Interview Transcript: Doctor of Medicine

24.6. Company E

24.6.1. Company Snapshot

24.6.2. Interview Transcript: Professor

24.7. Company F

24.7.1. Company Snapshot

24.7.2. Interview Transcript: Professor of Medicine and Heart Failure Specialist (Former Chair of Division for Circulatory Failure)

24.8. Company G

24.8.1. Company Snapshot

24.8.2. Interview Transcript: Senior Consultant Cardiologist

24.9. Company H

24.9.1. Company Snapshot

24.9.2. Interview Transcript: Professor and Chair of DIGIT-HF trial

24.10. Company I

24.10.1. Company Snapshot

24.10.2. Interview Transcript: Cardiologist

+ 25. APPENDIX I: TABULATED DATA

+ 26. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

+ List of Figures

Figure 2.1 Research Methodology: Project Methodology

Figure 2.2 Research Methodology: Data Sources for Secondary Research

Figure 2.3 Research Methodology: Robust Quality Control

Figure 3.1 Market Dynamics: Forecast Methodology

Figure 3.2 Market Dynamics: Market Assessment Framework

Figure 4.1 Lessons Learnt from Past Recessions

Figure 5.1 Executive Summary: Market Landscape

Figure 5.2 Executive Summary: Market Trends

Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis

Figure 6.1 Stages of Heart Failure

Figure 7.1 Heart Failure Drugs: Distribution by Stage of Development

Figure 7.2 Heart Failure Drugs: Distribution by Type of Molecule

Figure 7.3 Heart Failure Drugs: Distribution by Type of Biologic

Figure 7.4 Heart Failure Drugs: Distribution by Type of Therapy

Figure 7.5 Heart Failure Drugs: Distribution by Mechanism of Action

Figure 7.6 Heart Failure Drugs: Distribution by Route of Administration

Figure 7.7 Heart Failure Drugs: Distribution by Target Patient Population

Figure 7.8 Heart Failure Drugs: Distribution by Type of Heart Failure

Figure 7.9 Heart Failure Drug Developers: Distribution by Year of Establishment

Figure 7.10 Heart Failure Drug Developers: Distribution by Company Size

Figure 7.11 Heart Failure Drug Developers: Distribution by Location of Headquarters

Figure 7.12 Most Active Players: Distribution by Number of Drugs Developed

Figure 9.1 Clinical Trial Analysis: Distribution by Trial Registration Year

Figure 9.2 Clinical Trial Analysis: Distribution by Trial Status

Figure 9.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status

Figure 9.4 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Phase

Figure 9.5 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Registration Year

Figure 9.6 Clinical Trial Analysis: Distribution by Trial Phase

Figure 9.7 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator

Figure 9.8 Clinical Trial Analysis: Distribution by Patient Gender

Figure 9.9 Clinical Trial Analysis: Distribution by Study Design

Figure 9.10 Clinical Trial Analysis: Distribution by Target Patient Population

Figure 9.11 Most Active Industry Players: Distribution by Number of Clinical Trials

Figure 9.12 Most Active Non-Industry Players: Distribution by Number of Clinical Trials

Figure 9.13 Clinical Trial Analysis: Geographical Distribution of Trials and Number of Patients Enrolled

Figure 9.14 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography

Figure 9.15 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography

Figure 10.1 Drug Failure Analysis: Distribution by Trial Phase

Figure 10.2 Drug Failure Analysis: Distribution by Trial Status

Figure 10.3 Drug Failure Analysis: Distribution by Reason of Drug Discontinuation

Figure 10.4 Drug Failure Analysis: Distribution by Study Start Year and Year of Discontinuation

Figure 10.5 Drug Failure Analysis: Distribution by Type of Heart Failure

Figure 10.6 Drug Failure Analysis: Distribution by Type of Sponsor

Figure 10.7 Drug Failure Analysis: Distribution by Geographical Region

Figure 12.1 Global Heart Failure Drugs Market: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 12.2 Global Heart Failure Drugs Market: Forecasted Estimates (Till 2035) (USD Billion), Conservative Scenario

Figure 12.3 Global Heart Failure Drugs Market: Forecasted Estimates (Till 2035) (USD Billion), Optimistic Scenario

Figure 13.1 Heart Failure Drugs Market for Chronic Heart Failure: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 13.2 Heart Failure Drugs Market for Others: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 14.1 Heart Failure Drugs Market for Monotherapies: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 14.2 Heart Failure Drugs Market for Combination Therapies: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 15.1 Heart Failure Drugs Market for Small Molecules: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 15.2 Heart Failure Drugs Market for Biologics: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 16.1 Heart Failure Drugs Market for Oral Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 16.2 Heart Failure Drugs Market for Subcutaneous Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 16.3 Heart Failure Drugs Market for Intramyocardial Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 16.4 Heart Failure Drugs Market for Intravenous Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 16.5 Heart Failure Drugs Market for Intracoronary Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 17.1 Heart Failure Drugs Market in North America: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 17.2 Heart Failure Drugs Market in the US: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 17.3 Heart Failure Drugs Market in Canada: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 17.4 Heart Failure Drugs Market in Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 17.5 Heart Failure Drugs Market in Germany: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 17.6 Heart Failure Drugs Market in France: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 17.7 Heart Failure Drugs Market in UK: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 17.8 Heart Failure Drugs Market in Italy: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 17.9 Heart Failure Drugs Market in Spain: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 17.10 Heart Failure Drugs Market in Rest of Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 17.11 Heart Failure Drugs Market in Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 17.12 Heart Failure Drugs Market in China: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 17.13 Heart Failure Drugs Market in Japan: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 17.14 Heart Failure Drugs Market in India: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 17.15 Heart Failure Drugs Market in South Korea: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 17.16 Heart Failure Drugs Market in Rest of Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 17.17 Heart Failure Drugs Market in Rest of the World: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 22.1 Heart Failure Drugs Market Empagliflozin / Jardiance: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 22.2 Heart Failure Drugs Market for Farxiga / Dapagliflozin: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 22.3 Heart Failure Drugs Market for Kerendia / Finerenone: Historical Trends (Since 2025) and Forecasted Estimates (Till 2035)

Figure 22.4 Heart Failure Drugs Market for Furoscix / Furosemide: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Figure 22.5 Heart Failure Drugs Market for Injectafer / Ferinject: Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)

Figure 22.6 Heart Failure Drugs Market for Verquvo / Vericiguat: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

Figure 22.7 Heart Failure Drugs Market for Sotagliflozin / Inpefa: Historical Trends (Since 2025) and Forecasted Estimates (Till 2035)

Figure 22.8 Heart Failure Drugs Market for Baxdrostat: Forecasted Estimates (Till 2035)

Figure 22.9 Heart Failure Drugs Market for Balcinrenone / Dapagliflozin: Forecasted Estimates (Till 2035)

Figure 22.10 Heart Failure Drugs Market for Vicadrostat / BI 690517: Forecasted Estimates (Till 2035)

Figure 22.11 Heart Failure Drugs Market for Ziltivekimab: Forecasted Estimates (Till 2035)

Figure 22.12 Heart Failure Drugs Market for Revascor / Rexlemestrocel L: Forecasted Estimates (Till 2035)

Figure 22.13 Heart Failure Drugs Market for Maridebart cafraglutid: Forecasted Estimates (Till 2035)

Figure 22.14 Heart Failure Drugs Market for Omecamtiv Mecarbil: Forecasted Estimates (Till 2035)

Figure 22.15 Heart Failure Drugs Market for Ferric Derisomaltose: Forecasted Estimates (Till 2035)

Figure 22.16 Heart Failure Drugs Market for JRM-001: Forecasted Estimates (Till 2035)

Figure 22.17 Heart Failure Drugs Market for Enavogliflozin / Envlo: Forecasted Estimates (Till 2035)

+ List of Tables

Table 7.1 List of Heart Failure Drugs

Table 7.2 List of Heart Failure Drug Developers

Table 9.1 Heart Failure Drugs: List of Clinical Trials, Since 2021

Table 10.1 List of Discontinued Heart Failure Drugs

Table 12.1 List of Heart Failure Drugs Forecasted

Table 25.1 Heart Failure Drugs Market: Distribution by Stage of Development

Table 25.2 Heart Failure Drugs: Distribution by Type of Molecule

Table 25.3 Heart Failure Drugs: Distribution by Type of Biologic

Table 25.4 Heart Failure Drugs: Distribution by Type of Therapy

Table 25.5 Heart Failure Drugs: Distribution by Mechanism of Action

Table 25.6 Heart Failure Drugs: Distribution by Route of Administration

Table 25.7 Heart Failure Drugs: Distribution by Target Patient Population

Table 25.8 Heart Failure Drugs: Distribution by Type of Heart Failure

Table 25.9 Heart Failure Drug Developers: Distribution by Year of Establishment

Table 25.10 Heart Failure Drug Developers: Distribution by Company Size

Table 25.11 Heart Failure Drug Developers: Distribution by Location of Headquarters

Table 25.12 Most Active Players: Distribution by Number of Drugs Developed

Table 25.13 Clinical Trial Analysis: Distribution by Trial Registration Year

Table 25.14 Clinical Trial Analysis: Distribution by Trial Status

Table 25.15 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status

Table 25.16 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Phase

Table 25.17 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Registration Year

Table 25.18 Clinical Trial Analysis: Distribution by Trial Phase

Table 25.19 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator

Table 25.20 Clinical Trial Analysis: Distribution by Patient Gender

Table 25.21 Clinical Trial Analysis: Distribution by Study Design

Table 25.22 Clinical Trial Analysis: Distribution by Target Patient Population

Table 25.23 Most Active Industry Players: Distribution by Number of Clinical Trials

Table 25.24 Most Active Non-Industry Players: Distribution by Number of Clinical Trials

Table 25.25 Clinical Trial Analysis: Geographical Distribution of Trials and Number of Patients Enrolled

Table 25.26 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography

Table 25.27 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography

Table 25.28 Drug Failure Analysis: Distribution by Trial Phase

Table 25.29 Drug Failure Analysis: Distribution by Trial Status

Table 25.30 Drug Failure Analysis: Distribution by Reason of Drug Discontinuation

Table 25.31 Drug Failure Analysis: Distribution by Study Start Year and Year of Discontinuation

Table 25.32 Drug Failure Analysis: Distribution by Type of Heart Failure

Table 25.33 Drug Failure Analysis: Distribution by Type of Sponsor

Table 25.34 Drug Failure Analysis: Distribution by Geographical Region

Table 25.35 Global Heart Failure Drugs Market: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Billion)

Table 25.36 Global Heart Failure Drugs Market: Forecasted Estimates (Till 2035) (USD Billion), Conservative Scenario

Table 25.37 Global Heart Failure Drugs Market: Forecasted Estimates (Till 2035) (USD Billion), Optimistic Scenario

Table 25.38 Heart Failure Drugs Market for Chronic Heart Failure: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.39 Heart Failure Drugs Market for Others: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.40 Heart Failure Drugs Market for Monotherapies: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.41 Heart Failure Drugs Market for Combination Therapies: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.42 Heart Failure Drugs Market for Small Molecules: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.43 Heart Failure Drugs Market for Biologics: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.44 Heart Failure Drugs Market for Oral Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.45 Heart Failure Drugs Market for Subcutaneous Route: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 25.46 Heart Failure Drugs Market for Intramyocardial Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.47 Heart Failure Drugs Market for Intravenous Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.48 Heart Failure Drugs Market for Intracoronary Route: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.49 Heart Failure Drugs Market in North America: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.50 Heart Failure Drugs Market in the US: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.51 Heart Failure Drugs Market in Canada: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.52 Heart Failure Drugs Market in Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.53 Heart Failure Drugs Market in Germany: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.54 Heart Failure Drugs Market in France: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.55 Heart Failure Drugs Market in UK: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.56 Heart Failure Drugs Market in Italy: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.57 Heart Failure Drugs Market in Spain: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.58 Heart Failure Drugs Market in Rest of Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.59 Heart Failure Drugs Market in Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.60 Heart Failure Drugs Market in China: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.61 Heart Failure Drugs Market in Japan: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.62 Heart Failure Drugs Market in India: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.63 Heart Failure Drugs Market in South Korea: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.64 Heart Failure Drugs Market in Rest of Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.65 Heart Failure Drugs Market in Rest of the World: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.66 Heart Failure Drugs Market Empagliflozin / Jardiance: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.67 Heart Failure Drugs Market for Farxiga / Dapagliflozin: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Table 25.68 Heart Failure Drugs Market for Kerendia / Finerenone: Historical Trends (Since 2025) and Forecasted Estimates (Till 2035)

Table 25.69 Heart Failure Drugs Market for Furoscix / Furosemide: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 25.70 Heart Failure Drugs Market for Injectafer / Ferinject: Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)

Table 25.71 Heart Failure Drugs Market for Verquvo / Vericiguat: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

Table 25.72 Heart Failure Drugs Market for Sotagliflozin / Inpefa: Historical Trends (Since 2025) and Forecasted Estimates (Till 2035)

Table 25.73 Heart Failure Drugs Market for Baxdrostat: Forecasted Estimates (Till 2035)

Table 25.74 Heart Failure Drugs Market for Balcinrenone / Dapagliflozin: Forecasted Estimates (Till 2035)

Table 25.75 Heart Failure Drugs Market for Vicadrostat / BI 690517: Forecasted Estimates (Till 2035)

Table 25.76 Heart Failure Drugs Market for Ziltivekimab: Forecasted Estimates (Till 2035)

Table 25.77 Heart Failure Drugs Market for Revascor / Rexlemestrocel L: Forecasted Estimates (Till 2035)

Table 25.78 Heart Failure Drugs Market for Maridebart cafraglutid: Forecasted Estimates (Till 2035)

Table 25.79 Heart Failure Drugs Market for Omecamtiv Mecarbil: Forecasted Estimates (Till 2035)

Table 25.80 Heart Failure Drugs Market for Ferric Derisomaltose: Forecasted Estimates (Till 2035)

Table 25.81 Heart Failure Drugs Market for JRM-001: Forecasted Estimates (Till 2035)

Table 25.82 Heart Failure Drugs Market for Enavogliflozin / Envlo: Forecasted Estimates (Till 2035)

Heart Failure Drugs Market

Market Outlook

Market Report: Key Takeaways

Market Size & Trends

Key Market Statistics

Market Introduction

Market Segmentation

Heart Failure Drugs Market Key Insights

What are the Key Drivers for Heart Failure Drugs Market Growth?

What are the Main Challenges in Market Growth?

Recent Developments in Heart Failure Drugs Market

Industry Experts on Heart Failure Drugs Market Trends

Which Type of Heart Failure Accounts for the Largest Share in the Heart Failure Drugs Market?

Regional Analysis: Which Regions are Showing the Fastest Growth in Heart Failure Domain?

North America: Dominating the Market by Securing Highest Share

UAE Heart Failure Treatment Drugs Market

Which Type of Molecule Will Dominate the Heart Failure Drugs Market?

Which Route of Administration Accounts for the Largest Share in the Heart Failure Drugs Market?

Amongst Monotherapies and Combination Therapies, Which Segment Holds the Highest Share in the Heart Failure Drugs Market?

Scope of Heart Failure Drugs Market Report

Table of Contents

+ List of Figures

+ List of Tables

The Future of Autonomous Deliveries: Integrating Drones and Self-Driving Vehicles

Radiopharmaceutical Manufacturing: A Multi-Disciplinary Endeavour for Medical Imaging and Interventional Treatment

Heart Failure Drugs Market

Market Outlook

Market Report: Key Takeaways

Market Size & Trends

Key Market Statistics

Market Introduction

Market Segmentation

Heart Failure Drugs Market Key Insights

What are the Key Drivers for Heart Failure Drugs Market Growth?

What are the Main Challenges in Market Growth?

Recent Developments in Heart Failure Drugs Market

Industry Experts on Heart Failure Drugs Market Trends

Market Share Insights

Which Type of Heart Failure Accounts for the Largest Share in the Heart Failure Drugs Market?

Regional Analysis: Which Regions are Showing the Fastest Growth in Heart Failure Domain?

North America: Dominating the Market by Securing Highest Share

UAE Heart Failure Treatment Drugs Market

Which Type of Molecule Will Dominate the Heart Failure Drugs Market?

Which Route of Administration Accounts for the Largest Share in the Heart Failure Drugs Market?

Amongst Monotherapies and Combination Therapies, Which Segment Holds the Highest Share in the Heart Failure Drugs Market?

Scope of Heart Failure Drugs Market Report

Table of Contents

+ List of Figures

+ List of Tables

The Future of Autonomous Deliveries: Integrating Drones and Self-Driving Vehicles

Radiopharmaceutical Manufacturing: A Multi-Disciplinary Endeavour for Medical Imaging and Interventional Treatment